Reed Jobs prioritizes cancer cures as Yosemite expands AI-driven biotech venture

Three years after a TechCrunch Disrupt interview when Yosemite was a fledgling venture and the biotech sector was still recovering from a post‑pandemic downturn, the company has expanded its operations and strategic focus. Founder and CEO Jobs, who was first introduced to the audience during that earlier conversation, now leads a team of 17 employees. The firm is capitalising on a convergence of market forces: a wave of blockbuster drugs is approaching the end of their patent protection within a narrow timeframe, opening a suite of development opportunities for new entrants.

In response, Yosemite has integrated artificial intelligence into the core of its research and development pipeline, a shift Jobs described as “a huge part of what Yosemite does.” He added, “I didn’t expect Yosemite to be moving this fast.” The combination of a larger talent pool, imminent patent expirations, and AI‑driven capabilities positions the venture to pursue novel therapeutics and capture market share as legacy drugs lose exclusivity.